News

Cytori Therapeutics, Inc., a company focused on developing autologous cell therapies from adipose tissue for the treatment of several conditions, recently announced sustained positive results from its SCLERADEC-I clinical trial assessing the effects of Cytori Cell Therapy (ECCS-50) in patients with hand dysfunction related to scleroderma. Specifically, the company reported that…

Throughout 2015, Scleroderma News reported on studies characterizing scleroderma disease subsets, unique features, case reports, potential therapies and strategies for symptom management. As the year comes to an end, here are the top 10 articles that generated the most interest among Scleroderma News readers, as registered by total views. Here are the…

Boehringer Ingelheim recently announced the enrollment of the first patient in the Phase 3 clinical trial SENSCIS (Safety and Efficacy of Nintedanib in Systemic SClerosIS) evaluating the safety and efficacy of the company’s product nintedanib (OFEV) in patients with systemic sclerosis and interstitial lung disease. Systemic sclerosis is a rare, chronic autoimmune…

Protagen AG, a leader in the development of novel molecular diagnostics for autoimmune diseases, recently launched the Multilisa BICD2, an ELISA (enzyme-linked immunosorbent assay) that together with clinical symptoms will aid on the diagnosis of systemic sclerosis (SSc). SSc is a complex, multi-organ autoimmune disease characterized by increased fibroblast…

Researchers  in Switzerland recently presented data revealing that patients with systemic sclerosis are likely to be deficient in certain micronutrients, and the deficiencies correlate with their disease. The data was presented at the American College of Rheumatology (ACR) Annual Meeting, held in San Francisco in November, and the abstract is…

A new and promising way of classifying the debilitating autoimmune disease scleroderma has been developed by researchers in Australia. Their study, published in the journal Arthritis and Rheumatology, is titled “Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components…

A novel way of identifying systemic sclerosis (SSc) patients with a high likelihood of digital ulcers could lead to them being given preventive therapy that may greatly benefit the quality and length of their lives. The categorization system is detailed in a study titled “Elucidating the burden of recurrent and chronic digital…

A new case study revealed that long-term treatment with therapeutic plasma exchange (TPE) led to successful symptom management and disease remission in a patient with CREST syndrome, or limited systemic scleroderma. The study, recently presented at the AABB Annual Meeting in California, is entitled “Benefit of Long-Term Therapeutic Plasma…

iBio, Inc., a biotechnology company focused on developing plant-based therapies for diseases that include scleroderma, recently presented new data on the company’s anti-fibrotic drug candidate IBIO-CFB03. The data were presented at the 2015 American College of Rheumatology (ACR) annual meeting, recently held in San Francisco, California. IBIO-CFB03 is…

miRagen Therapeutics, Inc, a biopharmaceutical company working to develop microRNA-based therapeutic agents for a range of diseases, recently announced the initiation of a Phase I clinical study assessing MRG-201, the company’s lead anti-fibrotic candidate, in healthy patients. The study has the potential to be extended to patients with cutaneous scleroderma. MRG-201…